Anyone know anything about this ?
PIERIS Releases Human Anticalin(R) Library with More than 10 Billion Structures
WEIHENSTEPHAN, Germany, Nov. 13 /PRNewswire/ -- PIERIS Proteolab AG, a private German biotechnology company, today announced the release of a novel human Anticalin® library based on its proprietary Anticalin® technology. The new library, named Theracalin®, uses a fully human protein scaffold which is derived from the lipocalin family of proteins, and contains more than 10 billion unique, human Anticalins®, specifically well suited for protein-based therapeutic drug development of proteins.
``For the first time there could be a true alternative to antibodies within the entire life science industry which is striving for the development of novel protein therapeutics,'' said Dr. Martin Poehlchen, CEO of the Company. ``We have optimised the generation of Anticalins® to get high affinity binders to a given target within days. Apart from building our own broad product portfolio we offer our Theracalin® library within biotech and pharma collaborations where the partner provides the biological target,'' said Dr. Poehlchen.
``Anticalins® offer several advantages compared with current applications of antibodies. For example they are smaller than antibodies or their commonly used fragments and they only consist of a single polypeptide chain. Anticalins® can be easily produced in E. coli and do not depend on an expensive fermentation in mammalian cells like antibodies. Furthermore bispecific receptor proteins, so called Duocalins® can be generated. We have also demonstrated the generation of high affinity binders beyond the nanomolar range,'' comments Steffen Schlehuber, CSO of PIERIS.
PIERIS is a biopharmaceutical company focused on the development and commercialization of Anticalin® therapies and diagnostics for a variety of diseases and other applications in the life science industry. Anticalins® are engineered receptor proteins with antibody-like functions derived from lipocalins. The Company has developed the revolutionary Anticalin® technology to enable the rapid generation of high affinity human protein product candidates to defined disease targets. PIERIS uses its Anticalin® technology to build a large and diversified product portfolio through the establishment of licensing arrangements with multiple pharmaceutical, biotechnology and genomics companies and through the development of its own internal proprietary products.
This news release may contain predictions and other forward-looking statements that involve risks and uncertainties, including whether and when any new products are successfully introduced. PIERIS disclaims, however, any intent or obligation to update these forward-looking statements.
Anticalin(s)®, Theracalin®, Duocalin®, PIERIS Proteolab®, and the Company's logo are registered trademarks or service marks of PIERIS.
SOURCE: PIERIS Proteolab AG |
